{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:34Z","timestamp":1789614154299,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104898","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:05:40Z","timestamp":1787155540000},"page":"104898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Leveraging endocrine sensitivity in ER-positive DCIS: Neoadjuvant therapy and nonoperative management"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8670-4357","authenticated-orcid":false,"given":"Ryoko","family":"Semba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davendra","family":"Segara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Bruce","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiko","family":"Shien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Birrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiya","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Kutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41392-024-01779-3","article-title":"Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"11","key":"10.1016\/j.breast.2026.104898_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.7326\/0003-4819-127-11-199712010-00014","article-title":"Using autopsy series to estimate the disease \"reservoir\" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?","volume":"127","author":"Welch","year":"1997","journal-title":"Ann Intern Med"},{"issue":"33","key":"10.1016\/j.breast.2026.104898_bib3","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2015.61.4743","article-title":"Lobular carcinoma in situ: a 29-Year longitudinal experience evaluating clinicopathologic features and breast cancer risk","volume":"33","author":"King","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104898_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-07-1127","article-title":"Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution","volume":"14","author":"Allred","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104898_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-014-1609-3","article-title":"Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype","volume":"465","author":"Van Bockstal","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.breast.2026.104898_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41523-020-0167-x","article-title":"Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions","volume":"6","author":"Bergholtz","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104898_bib7","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1245\/s10434-010-1407-3","article-title":"Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component","volume":"18","author":"Yu","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104898_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10549-023-07016-9","article-title":"Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact","volume":"201","author":"Schandiz","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13058-025-01990-2","article-title":"B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses","volume":"27","author":"Bergholtz","year":"2025","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2026.104898_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2128","article-title":"Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer","volume":"10","author":"Tamimi","year":"2008","journal-title":"Breast Cancer Res"},{"issue":"16","key":"10.1016\/j.breast.2026.104898_bib11","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jjco\/hyae122","article-title":"Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives","volume":"55","author":"Kanbayashi","year":"2025","journal-title":"Jpn J Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104898_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - the LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2026.104898_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076022","article-title":"Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study","volume":"383","author":"Schmitz","year":"2023","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.breast.2026.104898_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"van Seijen","year":"2019","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104898_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pky063","article-title":"Epidemiology, biology, treatment, and prevention of ductal carcinoma in situ (DCIS)","volume":"2","author":"Punglia","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"21","key":"10.1016\/j.breast.2026.104898_bib17","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa1206809","article-title":"Effect of three decades of screening mammography on breast-cancer incidence","volume":"367","author":"Bleyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2026.104898_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jamaoncol.2016.0525","article-title":"Management of ductal carcinoma in situ of the breast: a review","volume":"2","author":"Shah","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104898_bib19","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clbc.2020.10.007","article-title":"Cost-effectiveness analysis of biological signature DCISionRT use for DCIS treatment","volume":"21","author":"Kim","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2026.104898_bib20","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2025.07.1411","volume":"123","author":"Vicini","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10445","key":"10.1016\/j.breast.2026.104898_bib21","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","article-title":"Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment","volume":"403","author":"Delaloge","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2026.104898_bib22","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2010.34.0141","article-title":"Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24","volume":"30","author":"Allred","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(14)71171-4","article-title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial","volume":"16","author":"Cuzick","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.breast.2026.104898_bib24","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1200\/JCO.22.02900","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive Neoplasia: a 10-Year Follow-Up of TAM-01 study","volume":"41","author":"Lazzeroni","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104898_bib25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2026.104898_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","article-title":"Letrozole in the neoadjuvant setting: the P024 trial","volume":"105","author":"Ellis","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"10.1016\/j.breast.2026.104898_bib27","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, Tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3 Pt 2","key":"10.1016\/j.breast.2026.104898_bib28","article-title":"Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer","volume":"12","author":"Dowsett","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104898_bib29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.breast.2026.104898_bib30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-023-01626-3","article-title":"Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK\/07\/015)","volume":"25","author":"Bliss","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"15","key":"10.1016\/j.breast.2026.104898_bib32","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.breast.2026.104898_bib33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jamasurg.2023.5113","article-title":"Presurgical oral tamoxifen vs transdermal 4-Hydroxytamoxifen in women with ductal carcinoma in situ: a randomized clinical trial","volume":"158","author":"Khan","year":"2023","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.breast.2026.104898_bib34","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1200\/JCO.19.00510","article-title":"Phase II single-arm study of preoperative letrozole for estrogen receptor-positive postmenopausal ductal carcinoma in situ: CALGB 40903 (Alliance)","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104898_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/1471-2407-9-285","article-title":"Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ","volume":"9","author":"Chen","year":"2009","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/bjc.2013.284","article-title":"Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment","volume":"109","author":"Takagi","year":"2013","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.breast.2026.104898_bib37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2026.104898_bib38","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1245\/s10434-021-10883-5","article-title":"Neoadjuvant endocrine therapy and delays in surgery for ductal carcinoma in situ: implications for the coronavirus pandemic","volume":"29","author":"Williams","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104898_bib39","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1158\/2767-9764.CRC-22-0263","article-title":"Identifying good candidates for active surveillance of ductal carcinoma in situ: insights from a large neoadjuvant endocrine therapy cohort","volume":"2","author":"Glencer","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40644-024-00672-0","article-title":"Predictive value of background parenchymal enhancement on breast magnetic resonance imaging for pathological tumor response to neoadjuvant chemotherapy in breast cancers: a systematic review","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.breast.2026.104898_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/jama.2024.26698","article-title":"Active monitoring with or without endocrine therapy for low-risk ductal carcinoma in situ: the COMET randomized clinical trial","volume":"333","author":"Hwang","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.breast.2026.104898_bib42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40644-024-00691-x","article-title":"Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials","volume":"24","author":"Alaeikhanehshir","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.breast.2026.104898_bib43","series-title":"Oral presentation at the San Antonio breast cancer symposium","author":"Ihe","year":"2025"},{"issue":"14","key":"10.1016\/j.breast.2026.104898_bib44","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.1158\/0008-5472.CAN-08-2660","article-title":"PIK3CA mutations in in situ and invasive breast carcinomas","volume":"70","author":"Miron","year":"2010","journal-title":"Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:28:45Z","timestamp":1789612125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0960977626002080"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104898","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging endocrine sensitivity in ER-positive DCIS: Neoadjuvant therapy and nonoperative management","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104898"}}